2025 Q3 -tulosraportti
Vain PDF
48 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
82 363
Myynti
Määrä
10 925
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 620 | - | - | ||
| 680 | - | - | ||
| 4 320 | - | - | ||
| 10 925 | - | - | ||
| 46 671 | - | - |
Ylin
0,388VWAP
Alin
0,372VaihtoMäärä
0,8 2 026 512
VWAP
Ylin
0,388Alin
0,372VaihtoMäärä
0,8 2 026 512
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 288 069 | 2 288 069 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 288 069 | 2 288 069 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 2.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10. | |
| 2025 Q2 -tulosraportti | 12.8. | |
| 2025 Q1 -tulosraportti | 29.4. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 31.10.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·20 t sittenWho benefits from keeping the stock down at low valuation figures? Could there be an interest in that, for future investors/manufacturers?
·1 päivä sitten · MuokattuThey can no longer deny that Dicot is sitting on something completely out of the ordinary! Those of us who have been around for a while have known about this, but it's always good that the company communicates the opportunities in the substance to us 🔥🔥🔥
·1 päivä sittenInteresting to look at shortability, everywhere it says it's not shortable but Nordnet can apparently decide themselves that it can be shorted, those who lend out their shares to the short-sellers obviously don't care about the stock's value !? Ok, it has no value until phase 2b has shown positive results, but at the same time, no negative signals have come that would indicate this total collapse from around 1 krona to 33 öre .. strange, I think !!
·2 päivää sittenIt looks like Dicot is preparing the market to understand the need to finance more development. Where will the new share issue land? Probably depends on how high the share price rises on hopes for the future. Probably not many months before talk of "securing financing for the next phase"?
·1 päivä sittenI largely agree here, last year in 2024 Dicot decided to carry out an issue of approximately SEK 125 million, primarily to finance the clinical phase 2a study of their leading drug candidate, LIB-01. In addition to the shares here, warrants were issued, so investors had the opportunity to subscribe for additional shares at a later date. Existing investors (both shareholders, management, founders) in the rights issue in 2024 already subscribed for a significant portion (approx. 14 % of the issue) to maintain their ownership stake. This shows co-ownership and willingness to invest further. The issue was actually oversubscribed as Dicot received a total of approximately SEK 134.9 million from the issue. Considering that this could, of course, happen again with a new issue, I lean more towards one of these coming in from the sidelines in 2026/2027: Most obvious strategic players to buy/invest in Dico (who knows? maybe they are already in dialogue depending on agreed partial goals): Top 5 most logical: 1. Pfizer Pfizer itself created Viagra and remains a global leader in sexual health and has a history of acquiring/licensing new mechanisms. 2. Bayer Historically strong in urology and reproductive health. European cultural match + focus on lifestyle-related diseases. 3. Eli Lilly Strong in endocrinology and hormone therapies – tradition for innovation in niche indications. LIB-01’s mechanism of action fits directly into their area of interest within hormonal axes and sexual function. 4. AbbVie Specialist in niche indications, often works with smaller acquisitions early in development. Often willing to take clinical risk for exceptional upside. 5. Astellas Strong in urology and men's health. There are several other possibilities such as: Merck & Co. UCB Recordati GSK Takeda Of course, after positive phase-2 data Significantly higher probability for: • Full acquisition • Global licensing agreement • Regional exclusive agreement (USA / EU / APAC) However, in the meantime, there could also be life-science investment funds / venture funds bidding. But regardless, it's a very exciting case.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
48 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·20 t sittenWho benefits from keeping the stock down at low valuation figures? Could there be an interest in that, for future investors/manufacturers?
- ·1 päivä sitten · MuokattuThey can no longer deny that Dicot is sitting on something completely out of the ordinary! Those of us who have been around for a while have known about this, but it's always good that the company communicates the opportunities in the substance to us 🔥🔥🔥
- ·1 päivä sittenInteresting to look at shortability, everywhere it says it's not shortable but Nordnet can apparently decide themselves that it can be shorted, those who lend out their shares to the short-sellers obviously don't care about the stock's value !? Ok, it has no value until phase 2b has shown positive results, but at the same time, no negative signals have come that would indicate this total collapse from around 1 krona to 33 öre .. strange, I think !!
- ·2 päivää sittenIt looks like Dicot is preparing the market to understand the need to finance more development. Where will the new share issue land? Probably depends on how high the share price rises on hopes for the future. Probably not many months before talk of "securing financing for the next phase"?·1 päivä sittenI largely agree here, last year in 2024 Dicot decided to carry out an issue of approximately SEK 125 million, primarily to finance the clinical phase 2a study of their leading drug candidate, LIB-01. In addition to the shares here, warrants were issued, so investors had the opportunity to subscribe for additional shares at a later date. Existing investors (both shareholders, management, founders) in the rights issue in 2024 already subscribed for a significant portion (approx. 14 % of the issue) to maintain their ownership stake. This shows co-ownership and willingness to invest further. The issue was actually oversubscribed as Dicot received a total of approximately SEK 134.9 million from the issue. Considering that this could, of course, happen again with a new issue, I lean more towards one of these coming in from the sidelines in 2026/2027: Most obvious strategic players to buy/invest in Dico (who knows? maybe they are already in dialogue depending on agreed partial goals): Top 5 most logical: 1. Pfizer Pfizer itself created Viagra and remains a global leader in sexual health and has a history of acquiring/licensing new mechanisms. 2. Bayer Historically strong in urology and reproductive health. European cultural match + focus on lifestyle-related diseases. 3. Eli Lilly Strong in endocrinology and hormone therapies – tradition for innovation in niche indications. LIB-01’s mechanism of action fits directly into their area of interest within hormonal axes and sexual function. 4. AbbVie Specialist in niche indications, often works with smaller acquisitions early in development. Often willing to take clinical risk for exceptional upside. 5. Astellas Strong in urology and men's health. There are several other possibilities such as: Merck & Co. UCB Recordati GSK Takeda Of course, after positive phase-2 data Significantly higher probability for: • Full acquisition • Global licensing agreement • Regional exclusive agreement (USA / EU / APAC) However, in the meantime, there could also be life-science investment funds / venture funds bidding. But regardless, it's a very exciting case.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
82 363
Myynti
Määrä
10 925
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 620 | - | - | ||
| 680 | - | - | ||
| 4 320 | - | - | ||
| 10 925 | - | - | ||
| 46 671 | - | - |
Ylin
0,388VWAP
Alin
0,372VaihtoMäärä
0,8 2 026 512
VWAP
Ylin
0,388Alin
0,372VaihtoMäärä
0,8 2 026 512
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 288 069 | 2 288 069 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 288 069 | 2 288 069 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 2.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10. | |
| 2025 Q2 -tulosraportti | 12.8. | |
| 2025 Q1 -tulosraportti | 29.4. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 31.10.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
Vain PDF
48 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 2.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10. | |
| 2025 Q2 -tulosraportti | 12.8. | |
| 2025 Q1 -tulosraportti | 29.4. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 31.10.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·20 t sittenWho benefits from keeping the stock down at low valuation figures? Could there be an interest in that, for future investors/manufacturers?
- ·1 päivä sitten · MuokattuThey can no longer deny that Dicot is sitting on something completely out of the ordinary! Those of us who have been around for a while have known about this, but it's always good that the company communicates the opportunities in the substance to us 🔥🔥🔥
- ·1 päivä sittenInteresting to look at shortability, everywhere it says it's not shortable but Nordnet can apparently decide themselves that it can be shorted, those who lend out their shares to the short-sellers obviously don't care about the stock's value !? Ok, it has no value until phase 2b has shown positive results, but at the same time, no negative signals have come that would indicate this total collapse from around 1 krona to 33 öre .. strange, I think !!
- ·2 päivää sittenIt looks like Dicot is preparing the market to understand the need to finance more development. Where will the new share issue land? Probably depends on how high the share price rises on hopes for the future. Probably not many months before talk of "securing financing for the next phase"?·1 päivä sittenI largely agree here, last year in 2024 Dicot decided to carry out an issue of approximately SEK 125 million, primarily to finance the clinical phase 2a study of their leading drug candidate, LIB-01. In addition to the shares here, warrants were issued, so investors had the opportunity to subscribe for additional shares at a later date. Existing investors (both shareholders, management, founders) in the rights issue in 2024 already subscribed for a significant portion (approx. 14 % of the issue) to maintain their ownership stake. This shows co-ownership and willingness to invest further. The issue was actually oversubscribed as Dicot received a total of approximately SEK 134.9 million from the issue. Considering that this could, of course, happen again with a new issue, I lean more towards one of these coming in from the sidelines in 2026/2027: Most obvious strategic players to buy/invest in Dico (who knows? maybe they are already in dialogue depending on agreed partial goals): Top 5 most logical: 1. Pfizer Pfizer itself created Viagra and remains a global leader in sexual health and has a history of acquiring/licensing new mechanisms. 2. Bayer Historically strong in urology and reproductive health. European cultural match + focus on lifestyle-related diseases. 3. Eli Lilly Strong in endocrinology and hormone therapies – tradition for innovation in niche indications. LIB-01’s mechanism of action fits directly into their area of interest within hormonal axes and sexual function. 4. AbbVie Specialist in niche indications, often works with smaller acquisitions early in development. Often willing to take clinical risk for exceptional upside. 5. Astellas Strong in urology and men's health. There are several other possibilities such as: Merck & Co. UCB Recordati GSK Takeda Of course, after positive phase-2 data Significantly higher probability for: • Full acquisition • Global licensing agreement • Regional exclusive agreement (USA / EU / APAC) However, in the meantime, there could also be life-science investment funds / venture funds bidding. But regardless, it's a very exciting case.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
82 363
Myynti
Määrä
10 925
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 620 | - | - | ||
| 680 | - | - | ||
| 4 320 | - | - | ||
| 10 925 | - | - | ||
| 46 671 | - | - |
Ylin
0,388VWAP
Alin
0,372VaihtoMäärä
0,8 2 026 512
VWAP
Ylin
0,388Alin
0,372VaihtoMäärä
0,8 2 026 512
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 288 069 | 2 288 069 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 288 069 | 2 288 069 | 0 | 0 |